--- title: "Mounjaro vs Ozempic: Trials, Side Effects & Dosing (2026) | GLPMate" url: https://glpmate.me/blog/mounjaro-vs-ozempic-2026 language: en description: "Mounjaro vs Ozempic compared using US labels and the SURPASS-2 head-to-head trial: blood sugar, weight, side effects, dosing and what switching involves." updated: 2026-10-14 --- [Blog](/blog) # Mounjaro vs Ozempic: how tirzepatide and semaglutide compare for type 2 diabetes, weight and side effects By [the GLPMate team](/editorial-policy) · Based on FDA prescribing information & peer-reviewed sources · Updated 2026-10-14 · 7 min read Quick answer Mounjaro (tirzepatide) activates GIP and GLP-1 receptors; Ozempic (semaglutide) activates GLP-1 only. Both are weekly type 2 diabetes injections. In the 40-week SURPASS-2 trial, Mounjaro lowered HbA1c by 2.0–2.3 points vs 1.9 with semaglutide 1 mg, and weight by 7.6–11.2 kg vs 5.7 kg, with similar GI side effects. Which suits you, and any switch, is your prescriber's call. ## What is the difference between Mounjaro and Ozempic? Mounjaro and Ozempic are both once-weekly injections for type 2 diabetes, and both tend to lower body weight. The core difference is the molecule inside the pen. - **Mounjaro** contains **tirzepatide**, made by Eli Lilly. It activates two gut-hormone receptors, GIP and GLP-1, which is why its label calls it a dual GIP and GLP-1 receptor agonist. - **Ozempic** contains **semaglutide**, made by Novo Nordisk. It activates the GLP-1 receptor only. Both help the body release insulin when blood sugar is high, slow stomach emptying and reduce appetite. Each also has a sister brand approved for weight management: Zepbound (tirzepatide) and Wegovy (semaglutide), which have their own doses and approvals. We compare those in [Wegovy vs Zepbound](/blog/wegovy-vs-zepbound-2026). Ozempic is now also sold as a once-daily tablet in the US, but that’s a separate product; this article compares the weekly injections. **−11.2 kg vs −5.7 kg** Average weight change after 40 weeks in SURPASS-2 with tirzepatide 15 mg vs semaglutide 1 mg in adults with type 2 diabetes (−7.6 kg and −9.3 kg on tirzepatide 5 and 10 mg). The trial was open-label and funded by Eli Lilly, it didn't test semaglutide 2 mg, and individual results vary. ## Mounjaro vs Ozempic at a glance From the current US labels on DailyMed, checked 14 October 2026. Labels change, so your pharmacist has the final word. **Mounjaro** | **Ozempic** (injection) Active ingredient | Tirzepatide (GIP + GLP-1 receptor agonist) | Semaglutide (GLP-1 receptor agonist) Approved uses (US) | Blood sugar control in type 2 diabetes (adults and children 10+); lowering the risk of major heart events in adults with type 2 diabetes at high risk | Blood sugar control in adults with type 2 diabetes; lowering the risk of major heart events in those with established heart disease; lowering the risk of kidney decline, kidney failure and heart death in those with chronic kidney disease Starting dose | 2.5 mg weekly | 0.25 mg weekly for 4 weeks, then 0.5 mg Further steps | 2.5 mg increments, each after at least 4 weeks, if more glucose control is needed | 1 mg, then 2 mg, each after at least 4 weeks, if more glucose control is needed Maximum dose | 15 mg (10 mg in children) | 2 mg Presentations | Single-dose pens and vials; 4-dose vials and KwikPens | Multi-dose pens; single-dose syringes (0.25–1 mg) Missed dose | Take within 4 days, otherwise skip | Take within 5 days, otherwise skip Half-life | About 5 days | About 1 week ## What did the SURPASS-2 trial find? SURPASS-2 is the main head-to-head trial of the two molecules in type 2 diabetes (Frías et al., NEJM 2021). It enrolled 1,879 adults whose blood sugar wasn’t controlled on metformin and randomly assigned them to tirzepatide 5, 10 or 15 mg or semaglutide 1 mg once weekly for 40 weeks. Average HbA1c at the start was 8.28%. ### The results - **HbA1c** fell by 2.01, 2.24 and 2.30 percentage points on tirzepatide 5, 10 and 15 mg, compared with 1.86 points on semaglutide. The paper found every tirzepatide dose non-inferior and superior to semaglutide 1 mg. - **HbA1c below 7%** was reached by 82–86% on tirzepatide and 79% on semaglutide, according to the Mounjaro label’s summary of the trial. - **Body weight** changed by −7.6, −9.3 and −11.2 kg on tirzepatide, compared with −5.7 kg on semaglutide, from a starting weight of around 93 kg. - **Low blood sugar** below 54 mg/dL was uncommon: 0.2–1.7% on tirzepatide and 0.4% on semaglutide. - **Serious adverse events** were reported by 5–7% on tirzepatide and 3% on semaglutide. ### The caveats - The semaglutide dose was **1 mg**. Ozempic’s label now allows up to 2 mg, which SURPASS-2 didn’t test. - It was open-label (participants knew whether they were on tirzepatide or semaglutide) and funded by Eli Lilly, Mounjaro’s maker. - Forty weeks is a fairly short window, and the numbers are group averages, not predictions for any one person. ## Mounjaro vs Ozempic for weight loss: what can you expect? Neither Mounjaro nor Ozempic is approved specifically for weight loss. Weight change is a secondary effect in people being treated for type 2 diabetes. In SURPASS-2, the tirzepatide groups lost 1.9 to 5.5 kg more on average than the semaglutide 1 mg group, depending on dose. Two points help set expectations: - **Diabetes changes the numbers.** In the weight-management trials summarised on the Wegovy and Zepbound labels, people with type 2 diabetes lost less weight on average than people without it on the same medicine. - **The weight-focused versions are tested differently.** Zepbound and Wegovy were studied in people with obesity, and their head-to-head trial, SURMOUNT-5, is covered in our Wegovy vs Zepbound comparison. If your weight isn’t moving as hoped, bring your data to your prescriber rather than adjusting doses yourself. ## Mounjaro vs Ozempic side effects: how do they compare? The side-effect profiles are similar: mostly digestive, and mostly during dose increases. ### Head-to-head (SURPASS-2) - **Nausea:** 17–22% on tirzepatide vs 18% on semaglutide 1 mg - **Diarrhea:** 13–16% vs 12% - **Vomiting:** 6–10% vs 8% Most of these events were mild to moderate in both groups. ### From each label Each label also reports placebo-controlled pools from its own trials. These come from different studies, and both labels warn that rates can’t be directly compared across drugs. - **Mounjaro (5–15 mg):** any digestive side effect in 37–44% vs 20% on placebo; 3.0–6.6% stopped because of them vs 0.4% on placebo. - **Ozempic (0.5–1 mg):** any digestive side effect in 33–36% vs 15% on placebo; 3.1–3.8% stopped because of them vs 0.4% on placebo. Both labels say most nausea, vomiting and diarrhea happened during dose escalation. For practical tips, see our guide to [GLP-1 nausea relief](/blog/glp-1-nausea-relief-2026). ### Shared warnings The two labels carry the same core warnings: a boxed warning about thyroid C-cell tumors in rodents (neither should be used with a personal or family history of medullary thyroid cancer or MEN 2), acute pancreatitis, gallbladder problems, kidney injury from dehydration, severe digestive reactions, low blood sugar when combined with insulin or a sulfonylurea, worsening diabetic retinopathy with rapid glucose improvement, and a risk of aspiration under anesthesia. Tell your care team before any planned procedure. ## How do Mounjaro and Ozempic doses compare? Both labels start low and step up no faster than every 4 weeks, to reduce digestive side effects. Mounjaro climbs in 2.5 mg steps from 2.5 mg towards a 15 mg maximum. Ozempic moves from 0.25 mg to 0.5 mg, then to 1 mg and 2 mg if needed. In both cases, further steps happen only if more glucose control is needed. A few practical differences: - **Missed dose window:** within 4 days for Mounjaro, within 5 days for Ozempic. - **Changing your injection day:** at least 3 days between doses for Mounjaro, more than 2 days for Ozempic. - **The milligrams aren’t comparable.** A 5 mg tirzepatide dose isn’t “stronger” than 1 mg of semaglutide just because the number is bigger; they’re different molecules. Our [GLP-1 dose escalation schedule](/blog/glp-1-dose-escalation-schedule-2026) lays out every step for both. ## What does switching from Ozempic to Mounjaro involve? People switch for many reasons, from blood sugar not at target to side effects or supply. Switching is always prescriber-led, for good reasons: - **There’s no validated dose conversion** between semaglutide and tirzepatide. A UK pharmacy review notes there’s no regulator guidance on switching either, so clinicians often start low and titrate again. - **The Mounjaro label starts everyone at 2.5 mg** weekly, then steps up from there. - **Timing is a clinical decision.** Clinicians may start the new medicine on the next scheduled injection day or leave a short gap. Semaglutide’s half-life is about a week, so it stays in the body for around 5 weeks after the last Ozempic dose. - **Never take both together**, and don’t use leftover pens to bridge a gap. - **Side effects can come back** during the new titration, even if you’d settled on Ozempic. - **If you use insulin or a sulfonylurea,** ask how to monitor your glucose, because the risk of lows changes when diabetes medicines change. - **Get trained on the new device.** Pens, KwikPens and vials work differently, and the label asks for training whenever the presentation changes. Our guide to [switching GLP-1 medications](/blog/switching-glp-1-medications-2026) covers what to ask before, during and after a switch. ## When should you call your doctor? Contact your care team promptly, or get urgent help, if you notice: - Severe stomach pain that won’t go away, sometimes spreading to your back, with or without vomiting (possible pancreatitis) - Vomiting or diarrhea that stops you keeping fluids down, dizziness or passing very little urine (dehydration) - Pain in the upper stomach, fever, yellow skin or eyes (possible gallbladder problems) - Swelling of the face, lips, tongue or throat, or trouble breathing (possible allergic reaction; get help right away) - A lump in the neck, trouble swallowing or persistent hoarseness - Symptoms of low blood sugar if you also take insulin or a sulfonylurea, or new changes in your vision ## Tracking whichever medicine you take Trial averages only go so far; what matters is how your own body responds. GLPMate logs each dose with reminders, keeps a side-effect log with severity next to your weight trend, and turns it into a doctor report (PDF) for appointments, which is especially useful around a switch. See the [Mounjaro tracker](/mounjaro-tracker-app) or the [Ozempic tracker](/ozempic-tracker-app). This article is educational only and not medical advice. Talk to your prescriber before starting, stopping, switching or changing the dose of any medicine. FAQ ## FAQ ### Is Mounjaro stronger than Ozempic? In the SURPASS-2 trial, tirzepatide (Mounjaro) lowered HbA1c and body weight more on average than semaglutide 1 mg over 40 weeks in adults with type 2 diabetes. The trial didn't test Ozempic's 2 mg dose, and individual responses vary widely. Which medicine and dose suit you is a decision for your prescriber. ### Does Mounjaro or Ozempic cause more side effects? Both mainly cause digestive side effects such as nausea, diarrhea, vomiting and constipation, mostly while the dose is being increased. In SURPASS-2, nausea affected 17–22% on tirzepatide and 18% on semaglutide 1 mg, so rates were broadly similar. Tell your care team about side effects that are severe or don't settle. ### Can I switch from Ozempic to Mounjaro? Yes, but only with your prescriber. There is no validated dose conversion between semaglutide and tirzepatide, the Mounjaro label starts at 2.5 mg weekly, and side effects can return during the new titration. Never take both at the same time or work out a switch on your own. ### Can I take Mounjaro or Ozempic for weight loss without diabetes? In the US, Mounjaro and Ozempic are approved for type 2 diabetes. The same molecules are approved for weight management under different names: tirzepatide as Zepbound and semaglutide as Wegovy, with their own doses and approvals. Your doctor can explain which, if any, fits your situation. ## Sources 1. FDA Prescribing Information — Mounjaro (tirzepatide), DailyMed (revised 08/2026, checked 14 Oct 2026) — indications (type 2 diabetes in adults and children 10+, MACE risk reduction), 2.5 mg start and 2.5 mg steps to 15 mg, presentations, missed-dose rule, GI adverse-reaction rates, SURPASS-2 and SURPASS-CVOT results, half-life about 5 days 2. FDA Prescribing Information — Ozempic (semaglutide) injection, DailyMed (June 2026 version, checked 14 Oct 2026) — indications (type 2 diabetes, MACE risk reduction, CKD), 0.25/0.5/1/2 mg schedule, presentations, missed-dose rule, GI adverse-reaction rates, half-life about 1 week 3. Frías et al., NEJM 2021 (SURPASS-2) — tirzepatide 5/10/15 mg vs semaglutide 1 mg, 40 weeks, 1,879 adults with type 2 diabetes — HbA1c −2.01/−2.24/−2.30 vs −1.86 points; weight differences −1.9 to −5.5 kg; nausea, diarrhea and vomiting rates; hypoglycemia and serious adverse events; open-label, funded by Eli Lilly 4. FDA Prescribing Information — Rybelsus and Ozempic (oral semaglutide) tablets, DailyMed (August 2026 version, checked 14 Oct 2026) — Ozempic is also available as a once-daily tablet, a separate product not substitutable mg-for-mg 5. FDA Prescribing Information — Wegovy (semaglutide) and Zepbound (tirzepatide), DailyMed (checked 14 Oct 2026) — weight-management trials showing smaller average weight loss in people with type 2 diabetes than without it 6. Shahid, The Pharmaceutical Journal (Dec 2025, updated Jul 2026) — Switching between weight-loss medications — no validated dose equivalence between semaglutide and tirzepatide, no UK regulator guidance on switching, start-low approach and clinician-chosen timing Sources checked: October 14, 2026 This article is educational and is not medical advice, diagnosis or treatment. Medication decisions — including dose changes and what to do after a missed dose — belong with your prescriber. If you experience severe symptoms, seek medical care. ## Keep reading [Switching GLP-1 medications safely ](/blog/switching-glp-1-medications-2026)[GLP-1 dose escalation schedule ](/blog/glp-1-dose-escalation-schedule-2026)[Mounjaro tracker app ](/mounjaro-tracker-app) ## Start your GLP-1 journey with a companion that listens. Free to start. iOS & Android. [ Download on the **App Store** ](https://glpmate.go.link?adj_t=22klhq12&adj_campaign=blog-mounjaro-vs-ozempic-2026&adj_redirect_android=https%3A%2F%2Fapps.apple.com%2Fapp%2Fid6788548235&adj_redirect_macos=https%3A%2F%2Fapps.apple.com%2Fapp%2Fid6788548235&adj_redirect_windows=https%3A%2F%2Fapps.apple.com%2Fapp%2Fid6788548235) [ GET IT ON **Google Play** ](https://glpmate.go.link?adj_t=22klhq12&adj_campaign=blog-mounjaro-vs-ozempic-2026&adj_redirect_ios=https%3A%2F%2Fplay.google.com%2Fstore%2Fapps%2Fdetails%3Fid%3Dapp.eleutheromania.glpmate&adj_redirect_macos=https%3A%2F%2Fplay.google.com%2Fstore%2Fapps%2Fdetails%3Fid%3Dapp.eleutheromania.glpmate&adj_redirect_windows=https%3A%2F%2Fplay.google.com%2Fstore%2Fapps%2Fdetails%3Fid%3Dapp.eleutheromania.glpmate)